Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test

• Published in: British journal of cancer Vol. 112; no. 2; pp. 375 - 381
• Main Authors: Otero-Estévez, O, De Chiara, L, Rodríguez-Berrocal, F J, de la Cadena, M Páez, Cubiella, J, Castro, I, Gonzalez-Mao, C, Hernandez, V, Martínez-Zorzano, V S
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.01.2015; Nature Publishing Group
• Subjects: 692/53/2421; 692/699/67/1504/1885; 692/699/67/2322; Adenoma - blood; Adenoma - diagnosis; Adenoma - enzymology; Adult; Aged; Aged, 80 and over; Asymptomatic; Biomarkers, Tumor - blood; Biomedical and Life Sciences; Biomedicine; Blood tests; Cancer Research; Colonoscopy; Colorectal cancer; Colorectal Neoplasms - blood; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - enzymology; Dipeptidyl Peptidase 4 - blood; Double-Blind Method; Drug Resistance; Early Detection of Cancer; Epidemiology; Family medical history; Female; Gastroenterology; Humans; Immunoassay; Inflammatory bowel disease; Male; Medical research; Medical screening; Middle Aged; Molecular Diagnostics; Molecular Medicine; Occult Blood; Oncology; Prospective Studies; Risk; Sensitivity and Specificity; Tumors; Spain; colorectal cancer screening; family-risk; faecal immunochemical test; serum sCD26
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2014.605

Background: The development of specific screening programs for individuals with a family history of colorectal cancer (CRC) is a priority. This study evaluates the diagnostic performance of serum soluble CD26 (sCD26) in family-risk individuals and compares this marker with the faecal immunochemical test for the detection of advanced neoplasia (AN) (CRC or advanced adenomas; AA). Methods: Five hundred and sixteen asymptomatic individuals with at least one first-degree relative with CRC were included. Serum sCD26 was measured in all the individuals who also underwent a colonoscopy (53 AA and four cancer cases were found) and a faecal immunochemical test. Results: Setting specificity to 90% and 95%, respectively, sCD26 showed a sensitivity of 39.6% and 28.3% for AA, and of 42.1% and 28.1% for AN. The combination of sCD26 and the faecal test detected AA and AN with a 52.8% and 56.1% sensitivity, corresponding to 93.5% specificity. Conclusions: The combination of serum sCD26 and the faecal blood test could result a valuable strategy for detecting AN in familial-risk CRC screening.